217 related articles for article (PubMed ID: 36599117)
1. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.
Yoo M; Nelson RE; Cutshall Z; Dougherty M; Kohli M
JCO Oncol Pract; 2023 Mar; 19(3):e449-e456. PubMed ID: 36599117
[TBL] [Abstract][Full Text] [Related]
2. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
Li S; Li J; Peng L; Li Y; Wan X
Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
[No Abstract] [Full Text] [Related]
7. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
Shay R; Nicklawsky A; Gao D; Lam ET
Clin Genitourin Cancer; 2021 Aug; 19(4):370-370.e7. PubMed ID: 33674224
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India.
Gupta D; Singh A; Gupta N; Mehra N; Bahuguna P; Aggarwal V; Krishnamurthy MN; Roy PS; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
JCO Glob Oncol; 2023 Feb; 9():e2200246. PubMed ID: 36795991
[TBL] [Abstract][Full Text] [Related]
9. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
10. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
Front Public Health; 2022; 10():954264. PubMed ID: 36159269
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
[TBL] [Abstract][Full Text] [Related]
13. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
14. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.
Engel Ayer Botrel T; Datz Abadi M; Chabrol Haas L; da Veiga CRP; de Vasconcelos Ferreira D; Jardim DL
J Med Econ; 2021; 24(1):291-298. PubMed ID: 33538203
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
[No Abstract] [Full Text] [Related]
18. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Peng L
Clin Genitourin Cancer; 2023 Jun; 21(3):417.e1-417.e10. PubMed ID: 36529626
[TBL] [Abstract][Full Text] [Related]
19. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
20. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
